Halia Therapeutics to Present Final Phase 2 Ofirnoflast Data in Lower-Risk MDS at EHA2026 and Announces Appointment of Han Myint, MD, FACP, as Chief Medical Officer
- Written by PR Newswire
![]() |
European Hematology Association (EHA) oral presentation to report 67% hematological improvement, durable transfusion independence, and no treatment-related serious adverse events in ESA-refractory lower-risk MDS
Dr. Myint, a hematology leader and oncology drug-development executive, joins Halia to lead clinical development as ofirnoflast (HT-6184)...















